Introduction
============

The major histocompatibility complex (MHC), also known as human leukocyte antigen (HLA) in human, is associated with various autoimmune diseases. Especially, MHC class II genes show the strongest association with type 1 diabetes (T1D), in which *DRB1\*03-DQB1\*0201* and *DRB1\*04-DQB1\*0302* haplotypes in Caucasian and *DRB1\*0405-DQB1\*0401*, *DRB1\*0802-DQB1\*0302* and *DRB1\*0901-DQB1\*0303* haplotypes in Japanese confer susceptibility to the disease, while *DRB1\*15-DQB1\*0602* haplotype in Caucasian and *DRB1\*1501-DQB1\*0602* and *DRB1\*1502-DQB1\*0601* haplotypes in Japanese confer protection against the disease.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4],\ [@bib5]^

T1D is frequently accompanied by autoimmune thyroid disease (AITD), such as Graves\' disease (GD) and Hashimoto\'s thyroiditis (HT). The *DR3* haplotype in Caucasian and *DRB1\*0405-DQB1\*0401*, *DRB1\*0802-DQB1\*0302* and *DRB1\*0901-DQB1\*0303* haplotypes in Japanese confer susceptibility to T1D complicated with AITD.^[@bib6],\ [@bib7],\ [@bib8]^

AITD alone is also associated with MHC class II genes. The *DR3* haplotype confers susceptibility to GD and the *DR7* haplotype confers protection against GD,^[@bib9],\ [@bib10]^ in which arginine at position 74 of DR beta chain exhibits a strong association with the disease in Caucasian.^[@bib11],\ [@bib12]^ With less confidence, *DR3* and *DR4* haplotypes are associated with HT.^[@bib13],\ [@bib14],\ [@bib15]^

The MHC region shows the strongest susceptibility to T1D in animal models, such as NOD mice, BB rats, KDP rats and LEW.1AR1-*iddm* rats. Almost every rat model of T1D possesses the same 'u\' haplotype on the MHC class II loci (*RT1-B, -D*), suggesting that the class II 'u\' haplotype confers susceptibility to T1D in rats. Autoimmune thyroiditis (also known as HT in humans) with no clinical manifestation of hypothyroidism is frequently observed in BB and KDP rats.^[@bib16],\ [@bib17],\ [@bib18],\ [@bib19]^ In the analysis of backcross between BB rats (MHC class II 'u\' haplotype) and PVG.R23 rats ('a\' haplotype), u/u homozygous animals showed 88% diabetes and 45% thyroiditis; u/a heterozygous animals showed no diabetes and 64% thyroiditis, suggesting that 'u\' haplotype confers susceptibility to T1D but is susceptible or neutral to thyroiditis while 'a\' haplotype confers susceptibility to thyroiditis but is protective against T1D.^[@bib20]^ In another report, analysis of F2 intercross between BB and Fischer rats ('lv\' haplotype) found that u/u, u/lv and lv/lv animals showed 24, 24 and 0% thyroiditis, respectively, and analysis of backcross between BB and Lewis rats ('l\' haplotype) showed that u/u and u/l exhibited 25 and 31% thyroiditis, respectively.^[@bib21]^ These data suggest that 'u\' haplotype confers susceptibility to thyroiditis, and acts in a dominant manner against 'l\' and 'lv\' haplotypes. However, these results were based on the mixed genetic backgrounds such as backcross or intercross progeny. There has been no data on replacement of genetic backgrounds through the production of congenic strains. In KDP rats, thyroiditis frequently develops in animals showing no or late onset diabetes.^[@bib17],\ [@bib19]^ Thus, although the 'u\' haplotype is necessary for the development of T1D, the association of 'u\' and other haplotypes with T1D and thyroiditis remains unclear.

To clarify the role of MHC class II in the development of T1D and thyroiditis, we established and investigated a congenic strain carrying MHC class II 'a\' and 'u\' haplotypes on the KDP genetic background. To investigate the role of genetic background in the development of thyroiditis, we produced and investigated a congenic strain carrying *Cblb* mutation of the KDP rat on the PVG.R23 genetic background (MHC class II 'a\' haplotype).

Results
=======

Establishment of a KDP.PVG-*RT1*^*a/u*^ congenic strain
-------------------------------------------------------

By crossing the KDP and PVG.R23 rats followed by 11 successive backcrosses to the KDP, we successfully produced a congenic strain carrying the MHC class II 'a\' and 'u\' haplotypes (heterozygous state) on the KDP genetic background. Genome-wide profiling revealed that the region of \<14.6 Mb between p-terminus and *D20Rat60* on chromosome 20 harboring the MHC class II region of the PVG.R23 rat had been introgressed into the KDP genetic background, and that the PVG.R23 genome was not detected on other chromosomes ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). As the *Cblb* homozygous mutants have poor reproductive ability,^[@bib17],\ [@bib22]^ we have been maintaining the congenic strain having the *Cblb* region in the heterozygous state.

Incidence of diabetes of the KDP.PVG-*RT1*^*a/u*^ congenic strain
-----------------------------------------------------------------

We compared the incidence of T1D among the *Cblb* homozygous mutant animals with each of the three genotypes at MHC class II region in the congenic strain under the same specific pathogen-free condition ([Figure 1](#fig1){ref-type="fig"}). At 300 days of age, 88% (7/8) of u/u homozygous animals developed T1D similar to the original KDP rat,^[@bib22]^ and 37% (7/19) of a/u heterozygous animals did develop T1D but with delayed onset and low frequency. In contrast, none (0/11) of the a/a homozygous animals developed T1D. The u/u homozygous animals developed T1D as early as 50 days of age, while the a/u heterozygous animals developed the disease around 120 days of age at the earliest. Despite the low incidence and the delay of onset, it is noteworthy that the a/u heterozygous animals developed T1D.

Degree of insulitis and thyroiditis of the KDP.PVG-*RT1*^*a/u*^ congenic strain
-------------------------------------------------------------------------------

We then investigated the degree of insulitis and thyroiditis shortly after the onset of diabetes in diabetic animals and at 300 days of age in non-diabetic animals ([Figure 2](#fig2){ref-type="fig"}). All of the diabetic animals showed severe insulitis, whereas non-diabetic animals showed none to moderate insulitis: 100% (8/8) of u/u homozygous and 84% (16/19) of a/u heterozygous animals developed slight to severe insulitis. Although none of the a/a homozygous animals developed T1D, 45% (5/11) of them exhibited slight to moderate insulitis, suggesting that 'a\' haplotype did not confer complete protection against insulitis. In contrast to the severity of insulitis, thyroiditis was observed in 0% (0/8), 37% (7/19) and 55% (6/11) of u/u homozygous, a/u heterozygous and a/a homozygous animals, respectively ([Figure 2](#fig2){ref-type="fig"}). The serum thyroid stimulating hormone (TSH) values seem to be higher in a/a homozygous and a/u heterozygous animals than those of u/u homozygous animals, but there is no significant difference among them ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Furthermore, all of the TSH values are in normal range, suggesting no clinical manifestation of hypothyroidism.

To clarify the development of insulitis and thyroiditis in the congenic strain, we further investigated the degree of insulitis and thyroiditis at 120 days of age ([Figure 3](#fig3){ref-type="fig"}), at which 75% of u/u homozygous animals developed T1D while none of the a/u heterozygous animals developed diabetes. Slight to severe insulitis was observed in 100% (10/10), 83% (10/12) and 27% (3/11) of u/u homozygous, a/u heterozygous and a/a homozygous animals, respectively, the severity of which was milder than that at 300 days of age. At the same age, thyroiditis was observed in 20% (2/10), 8% (1/12) and 9% (1/11) of u/u homozygous, a/u heterozygous and a/a homozygous animals, respectively. The degree of thyroiditis was much milder than that of insulitis, suggesting that insulitis develops earlier than thyroiditis in these animals.

Establishment of a PVG.KDP-*Cblb* congenic strain
-------------------------------------------------

By crossing the KDP and PVG.R23 rats followed by seven successive backcrosses to the PVG.R23, we successfully produced a congenic strain carrying the mutated *Cblb* allele of the KDP rat on the PVG.R23 genetic background (MHC class II 'a\' haplotype). Genome-wide profiling revealed that the region of \<42.2 Mb between *D11Rat13* and *D11Rat37* on chromosome 11 harboring the mutated *Cblb* allele of the KDP rat had been introgressed into the PVG.R23 genetic background, and that the KDP genome was not detected on other chromosomes ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). As the *Cblb* homozygous mutants have poor reproductive ability,^[@bib17],\ [@bib22]^ we have been maintaining the congenic strain having the *Cblb* region in the heterozygous state.

Degree of insulitis and thyroiditis of the PVG.KDP-*Cblb* congenic strain
-------------------------------------------------------------------------

As expected, none of the animals in this congenic strain developed T1D before 300 days of age. We investigated the degree of insulitis and thyroiditis at 300 days of age, and found that 19% (4/21) of the *Cblb* homozygous mutants showed only slight insulitis, whereas heterozygous (*n*=10) and wild-type (*n*=10) animals exhibited no insulitis ([Figure 4](#fig4){ref-type="fig"}). At the same age, thyroiditis was observed in 38% (8/21) of the *Cblb* homozygous mutant animals, whereas none of the heterozygous (*n*=10) or wild-type (*n*=10) animals showed thyroiditis ([Figure 4](#fig4){ref-type="fig"}). The degree of insulitis and thyroiditis of the *Cblb* homozygous mutant animals is similar to that of a/a homozygous animals in the KDP.PVG-*RT1*^*a/u*^ congenic strain. There is no significant difference in the serum TSH values among animals with three genotypes of *Cblb* ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}) and all of the TSH values are in normal range, suggesting no clinical symptom of hypothyroidism. However, there was one *Cblb* homozygous mutant animal exhibiting an exceptionally high TSH value of more than 200 ngml^−1^. This animal also showed severe thyroiditis and severe hair loss (alopecia), indicating clinical manifestation of hypothyroidism such as HT.

Effect of iodide on the development of thyroiditis in the congenic strains
--------------------------------------------------------------------------

The NOD-*H2*^*h4*^ mice, which express MHC class II 'k\' haplotype on the NOD background, do not develop T1D but spontaneous autoimmune thyroiditis, which is accelerated by adding iodide in the drinking water.^[@bib23]^ To clarify the effect of iodide on the development of thyroiditis in the congenic strains, we supplied animals with 0.15% NaI in the drinking water for 4 weeks around 200 days of age. In the KDP.PVG-*RT1*^*a/u*^ congenic strain, thyroiditis was observed in 60% (6/10) and 27% (3/11) of a/u heterozygous and a/a homozygous animals, respectively ([Figure 5](#fig5){ref-type="fig"}). In the PVG.KDP-*Cblb* congenic strain, thyroiditis was observed in 50% (6/12) of the *Cblb* homozygous mutant animals ([Figure 5](#fig5){ref-type="fig"}). As there was no significant acceleration in the development of thyroiditis with iodide treatment for 4 weeks, we did not measure TSH levels in these animals.

Discussion
==========

In the present study, we investigated the role of MHC class II in the development of tissue-specific autoimmune diseases including T1D and autoimmune thyroiditis by use of newly established congenic strains. The results indicate that, under homozygosity for *Cblb* mutation, MHC class II 'u\' haplotype confers susceptibility to insulitis and T1D, while 'a\' haplotype confers protection against insulitis and T1D, in which 'u\' haplotype acts in a semidominant manner with respect to 'a\' haplotype. In contrast, under homozygosity for *Cblb* mutation, MHC class II 'u\' haplotype confers neutral susceptibility to thyroiditis, while 'a\' haplotype confers susceptibility to thyroiditis, in which 'a\' haplotype acts in a dominant or semidominant manner with respect to 'u\' haplotype. It should be noted that it is not T1D but thyroiditis that occurs in congenic rats with homozygosity for both MHC class II 'a\' haplotype and *Cblb* mutation. These findings support the previous report on the analysis of backcross between BB and PVG.R23 rats^[@bib20]^ but further clarifies the mode of inheritance of 'a\' and 'u\' haplotypes on the KDP genetic background. The length of the congenic interval found in each congenic strain varied. The relatively small cohort sizes of these experiments were underpowered to detect small effects caused by the congenic intervals. Larger cohorts are needed to detect more subtle effects of congenic intervals in T1D and thyroiditis.

To our knowledge, this study is the first analysis of the role of rat MHC class II haplotypes in the development of T1D and autoimmune thyroiditis in a genetic background susceptible to T1D using congenic strains. In addition to the BB, KDP and LEW.1AR1-*iddm* rats, spontaneous T1D also occurs (with a frequency of 2%) in LEW.1WR1 rats.^[@bib24]^ Almost all spontaneous or virus-induced T1D models in rat species possess 'u\' haplotype at MHC class II,^[@bib25]^ suggesting that the MHC class II 'u\' haplotype is required to develop T1D in rats. In humans, non-aspartic acid at position 57 of HLA-DQ beta chain of MHC class II is associated with T1D.^[@bib26]^ At position 57 of rat RT1-B beta, which is orthologous to HLA-DQ beta, the 'u\' allele possesses non-aspartic acid, while 'a\' allele possesses aspartic acid.^[@bib27]^ These findings indicate that the MHC class II molecule encoded by 'u\' but not 'a\' haplotype recognizes an unidentified epitope, among which an insulin epitope is the strong candidate,^[@bib28],\ [@bib29]^ and leads to islet-specific autoimmunity, resulting in T1D.

In humans, arginine at position 74 of HLA-DR beta chain of MHC class II has been reported to be strongly associated with GD.^[@bib11]^ At position 74 of rat RT1-D beta, which is orthologous to HLA-DR beta, both the 'u\' and 'a\' alleles possess alanine.^[@bib27]^ These indicate that both haplotypes are not likely to be susceptible to GD. Although there are no such data for HT, 'a\' but not 'u\' haplotype would be expected to possess amino acid(s) that confer susceptibility to HT. There has been no known spontaneous animal model exhibiting final pathophysiological states of AITD, including GD and HT. Although the BB and KDP rats show spontaneous autoimmune thyroiditis, they do not develop hypothyroidism. In this study, we also investigated whether combination of the thyroiditis-susceptible MHC class II haplotype 'a\' and the autoimmunity-susceptible *Cblb* mutation could induce hypothyroidism on two different genetic backgrounds such as the KDP and PVG.R23. Although 40--60% of animals in both strains developed thyroiditis, the TSH levels suggested no clinical symptom of hypothyroidism. However, in the PVG.KDP-*Cblb* congenic strain, 76% (16/21) of the *Cblb* homozygous mutant animals showed slight to severe alopecia, which is often found to be associated with hypothyroidism in humans. Only 19% (4/21) of these animals developed severe alopecia, while the others exhibited only slight to mild states. Furthermore, regrowth occurred spontaneously in many cases and the hair growth was restored within several months. These findings suggest the use of the PVG.KDP-*Cblb* congenic strain as a spontaneous animal model of HT. However, the low frequency of incidence of severe pathophysiological states makes practical use of this model difficult; iodide supplement from younger age and longer duration might induce hypothyroidism more frequently.

In conclusion, the roles of rat MHC class II 'a\' and 'u\' haplotype in the development of T1D and autoimmune thyroiditis differ. The congenic strains established in this study will be useful for the investigation of the pathogenesis and pathophysiology of tissue-specific autoimmune diseases, including T1D and thyroiditis.

Materials and methods
=====================

KDP and PVG.R23 rats
--------------------

Both KDP (*RT1.A*^*u*^*B*^*u*^*D*^*u*^*C*^*u*^) and PVG.R23 (*RT1.A*^*u*^*B*^*a*^*D*^*a*^*C*^*av1*^) rats were a kind gift from Dr K Komeda (Tokyo Medical University), and were maintained at the Institute for Experimental Animals, Kobe University School of Medicine. The KDP/Tky strain is available from Japan SLC, Inc. All animals were maintained under specific pathogen-free conditions at 23±2 °C and 55±10% relative humidity with a 12-h light--dark cycle, and were provided with water and a commercial diet CE-2 (CLEA Japan, Inc., Tokyo, Japan) at the Institute for Experimental Animals, Kobe University School of Medicine. All animal experiments were approved by the Committee on Animal Experimentation, Kobe University School of Medicine, and carried out in accordance with the 'Guidelines for Animal Experimentation at Kobe University\'.

KDP.PVG-*RT1*^*a/u*^ congenic strain
------------------------------------

The KDP and PVG.R23 rats were crossed to produce the F1 progeny. Eleven successive backcrosses (N12) to the KDP rats were needed to obtain animals heterozygous at MHC class II region but homozygous for KDP allele for the other regions. The *Cblb* region has been maintained in the heterozygous state to overcome the poor reproductive ability of the *Cblb* homozygous mutants.^[@bib17],\ [@bib22]^ An intercross between the N12 animals was conducted to obtain the congenic strain (N12F1) carrying MHC class II (*RT1-B, -D*) 'a\' and 'u\' haplotypes on the KDP genetic background. The congenic strain, named KDP.PVG-*RT1*^*a/u*^/Nyo, is available from the National Bio-Resource Project of Rat in Japan (<http://www.anim.med.kyoto-u.ac.jp/nbr/>).

PVG.KDP-*Cblb* congenic strain
------------------------------

The KDP and PVG.R23 rats were crossed to produce the F1 progeny. Seven successive backcrosses (N8) to the PVG.R23 rats were needed to obtain animals heterozygous at the *Cblb* region but homozygous for PVG.R23 allele for the other regions. An intercross between the N8 animals was conducted to obtain the congenic strain (N8F1) carrying the mutated *Cblb* allele of the KDP rat on the PVG.R23 genetic background. The congenic strain, named PVG.KDP-*Cblb*/Nyo, is available from the National Bio-Resource Project of Rat in Japan (<http://www.anim.med.kyoto-u.ac.jp/nbr/>).

Genotyping
----------

The simple sequence length polymorphism markers and PCR--RFLP markers used in this study have been described (Rat Genome Database, available at <http://rgd.mcw.edu/>).^[@bib17],\ [@bib22],\ [@bib30],\ [@bib31]^ Genotyping was performed as described in previous investigations.^[@bib17],\ [@bib22],\ [@bib30],\ [@bib31]^ Briefly, genomic DNA was extracted from the tail tip of each rat using the automatic DNA Isolation System (Kurabo, Osaka, Japan). PCR amplification was carried out using 200-n sense and antisense primers, 200 μ each dNTP, 12-ng genomic DNA and 0.75 U of LA *Taq* DNA polymerase (Takara Bio Inc., Shiga, Japan) in a total volume of 15 μl. The PCR product was mixed with loading buffer (0.03% bromphenol blue and 30% glycerol), electrophoresed on 4% NuSieve 3:1 agarose gel (FMC BioProducts, Rockland, ME, USA) and stained with ethidium bromide. For *Cblb*, genotyping was performed by PCR--RFLP analysis using primers, 5′-TGCCCCTTCTGTCGCTGTGA-3′ and 5′-CCTCGGTTTTGAATCAACAG-3′, and restriction enzyme *Taq*I. For *D20Rwh1* (*RT1-Bb*), genotyping was performed by PCR--RFLP analysis using primers, 5′-CACCAACGGGACGCAGCGCAT-3′ and 5′-CAAGCCGCCGCAGGGAGGTG-3′, and restriction enzyme *BssH*II. For *RT1-Db*, genotyping was performed by PCR--RFLP analysis using primers, 5′-ACGCAGCGCGTGCGGCTTCT-3′ and 5′-GCTCCATGAACTCCTTCTGTTTG-3′, and restriction enzyme *Dde*I.

Phenotyping of diabetes
-----------------------

Phenotyping was completed using a previously described protocol.^[@bib30]^ Diabetes was defined as glycosuria positivity and blood glucose levels **⩾**250 mg dl^−1^ under *ad libitum* dietary conditions. Data were obtained from two generations (N12F1 to N12F2) of the KDP.PVG-*RT1*^*a/u*^ congenic strain and two generations (N8F2 to N8F3) of the PVG.KDP-*Cblb* congenic strain.

Histological analysis
---------------------

Histological analysis was performed as described previously^[@bib17],\ [@bib30]^ with some modifications. Briefly, tissues were fixed in 10% formalin, and paraffin sections were stained with hematoxylin and eosin. Serial sections were viewed via light microscopy by an examiner blind to the experimental conditions of the animals. Each animal was rated on the degree of insulitis, which ranged from none to severe (none \[0%\], slight \[0%\<and lower than or equal to 5%\], mild \[5%\<and lower than or equal to 20%\], moderate \[20%\<and lower than or equal to 70%\], and severe \[70%\<\]) based mainly on the percentage of moderately and severely infiltrated islets. The term 'slight insulitis\' refers to at least one infiltrated islet across the sections and a percentage of infiltrated islets of 5% or less. Animals were also rated on the degree of thyroiditis, which ranged from none to severe (none, slight-mild and moderate-severe) based on the percentage of infiltrated regions in the thyroid sections. Data were obtained from two generations (N12F1 to N12F2) of the KDP.PVG-*RT1*^*a/u*^ congenic strain and two generations (N8F2 to N8F3) of the PVG.KDP-*Cblb* congenic strain, with the exception that the degree of insulitis and thyroiditis at 120 days of age was evaluated in the N12F5 generation of the KDP.PVG-*RT1*^*a/u*^ congenic strain.

TSH assay
---------

Serum TSH was measured with an enzyme-linked immunosorbent assay kit (Rat TSH ELISA KIT, Shibayagi, Gunma, Japan).

Iodide administration
---------------------

The a/u heterozygous and a/a homozygous animals in the KDP.PVG-*RT1*^*a/u*^ congenic strain and the *Cblb* homozygous mutant animals in the PVG.KDP-*Cblb* congenic strain were supplied with 0.15% NaI in the drinking water for 4 weeks around 200 days of age.

Statistical analysis
--------------------

Differences in the incidence of diabetes were assessed using log-rank tests. Differences in the degree of insulitis or thyroiditis were assessed using Mann--Whitney *U* tests. Differences in the TSH values were assessed using Tukey--Kramer method. Statistical analysis was performed by R.^[@bib32]^
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![Cumulative incidence of diabetes in the KDP.PVG-*RT1*^*a/u*^ congenic strain. Under the same specific pathogen-free condition, data of diabetes onset were obtained from the u/u homozygous (*n*=8), a/u heterozygous (*n*=19) and a/a homozygous (*n*=11) animals, all of which harbor the homozygous *Cblb* mutation. *P*\<0.001 for u/u vs a/u and u/u vs a/a, and *P*=0.027 for a/u vs a/a by log-rank tests.](gene201163f1){#fig1}

![Degree of insulitis and thyroiditis in the KDP.PVG-*RT1*^*a/u*^ congenic strain at 300 days of age. (**A**): Representative histology of the pancreas and thyroid glands in the congenic strain. a, normal islet; b, mild insulitis; c, severe insulitis; d, normal thyroid glands; e, mild thyroiditis; f, severe thyroiditis. (**B**) The degree of insulitis and thyroiditis in the congenic strain shortly after the onset of diabetes or at 300 days of age for non-diabetic animals. Data were obtained from the u/u homozygous (*n*=8), a/u heterozygous (*n*=19) and a/a homozygous (*n*=11) animals, all of which harbor the homozygous *Cblb* mutation. Insulitis: *P*=0.017 for u/u vs a/u, *P*\<0.001 for u/u vs a/a and *P*=0.020 for a/u vs a/a; Thyroiditis: *P*=0.050 for u/u vs a/u, *P*=0.016 for u/u vs a/a and *P*=0.573 for a/u vs a/a by Mann--Whitney *U* tests.](gene201163f2){#fig2}

![Degree of insulitis and thyroiditis in the KDP.PVG-*RT1*^*a/u*^ congenic strain at 120 days of age. The degree of insulitis and thyroiditis in each animal was evaluated shortly after the onset of diabetes or at 120 days of age for non-diabetic animals. Data were obtained from the u/u homozygous (*n*=10), a/u heterozygous (*n*=12) and a/a homozygous (*n*=11) animals, all of which harbor the homozygous *Cblb* mutation. Insulitis at 300 days vs 120 days: *P*=0.184 for u/u, *P*=0.202 for a/u and *P*=0.280 for a/a; Thyroiditis at 300 days vs 120 days: *P*=0.193 for u/u, *P*=0.055 for a/u and *P*=0.018 for a/a by Mann--Whitney *U* tests.](gene201163f3){#fig3}

![Degree of insulitis and thyroiditis in the PVG.KDP-*Cblb* congenic strain at 300 days of age. The degree of insulitis and thyroiditis in each animal was evaluated at 300 days of age. Data were obtained from the animals homozygous (*n*=21), heterozygous (*n*=10) and wild type (*n*=10) for the *Cblb* mutation. *P*=0.082 for insulitis and *P*=0.249 for thyroiditis by Mann--Whitney *U* tests in comparison between the a/a homozygous animals in the KDP.PVG-*RT1*^*a/u*^ congenic strain and the *Cblb* homozygous mutants in the PVG.KDP-*Cblb* congenic strain.](gene201163f4){#fig4}

![Degree of thyroiditis in the KDP.PVG-*RT1*^*a/u*^ and PVG.KDP-*Cblb* congenic strains with iodide treatment. The degree of thyroiditis in each animal was evaluated after 4 weeks of iodide treatment. Data were obtained from the a/u heterozygous (*n*=10) and a/a homozygous (*n*=11) animals in the KDP.PVG-*RT1*^*a/u*^ congenic strain, all of which harbor the homozygous *Cblb* mutation, and from the *Cblb* homozygous mutant animals (*n*=12) in the PVG.KDP-*Cblb* congenic strain. Thyroiditis in NaI treatment vs no treatment: *P*=0.682 for a/u heterozygous animals in the KDP.PVG-*RT1*^*a/u*^ congenic strain, *P*=0.218 for a/a homozygous animals in the KDP.PVG-*RT1*^*a/u*^ congenic strain and *P*=0.355 for the *Cblb* homozygous mutants in the PVG.KDP-*Cblb* congenic strain by Mann--Whitney *U* tests.](gene201163f5){#fig5}
